The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
Artur A SerebrenikProkopios P ArgyrisMatthew C JarvisWilliam L BrownMartina BazzaroRachel Isaksson VogelBritt K EricksonSun-Hee LeeKrista M GoergenMatthew John MaurerEthan P HeinzenAnn L ObergYajue HuangXiaonan HouS John WerohaScott H KaufmannReuben S HarrisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These studies demonstrate that APOBEC3B is overexpressed in a subset of CCOC and, contrary to initial expectations, associated with improved (not worse) clinical outcomes. A likely molecular explanation is that APOBEC3B-induced DNA damage sensitizes cells to additional genotoxic stress by cisplatin. Thus, APOBEC3B is a molecular determinant and a candidate predictive biomarker of the therapeutic response to platinum-based chemotherapy. These findings may have broader translational relevance, as APOBEC3B is overexpressed in many different cancer types.